[Abstract] [Full Text HTML] [Full Text PDF] (in Japanese / 1564KB) [PDF: Members Only]

J.Jpn. Surg. Soc.. 124(3): 233-238, 2023


Feature topic

CURRENT STATUS AND FUTURE PROSPECTS OF STRATIFIED MEDICINE FOR ESOPHAGEAL CANCER

Department of General Surgical Science, Gunma University, Maebashi, Japan

Hiroshi Saeki, Makoto Sohda, Makoto Sakai, Akihiko Sano

Esophageal cancer treatment has changed significantly in recent years. Surgery has been steered in the direction of minimally invasive procedures, and multidisciplinary treatment including perioperative treatment has developed due to the creation of new evidence for preoperative chemotherapy and postoperative adjuvant therapy. In addition, immune checkpoint inhibitors have become one of the key players in drug therapy for advanced and recurrent cancer, marking a major turning point. On the other hand, regarding stratified medicine, various investigations have been conducted mainly in clinical studies. In particular, there are many reports that nutritional evaluation before surgery is closely related to postoperative outcomes, and its clinical applications are expected. Moreover, it is necessary to develop a promising therapeutic effect predictor in order to choose the most appropriate therapy from various available modalities. In addition to biomarker research using tissue and blood samples, the development of new evaluation methods using blood tests and imaging modalities that are performed in daily clinical practice can give important perspectives. The development of stratified medicine is an important point for new developments in esophageal cancer treatment in the future. Therefore, basic and clinical fields should work together and make strenuous efforts to advance treatment protocols.


<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.